Roche to Present Results of P-III Trial for Ocrevus (ocrelizumab) at ECTRIMS 2018

 Roche to Present Results of P-III Trial for Ocrevus (ocrelizumab) at ECTRIMS 2018

Roche to Present Results of P-III Trial for Ocrevus (ocrelizumab) at ECTRIMS 2018

Shots:

  • The data includes results from P-III extension studies of OPERA I, OPERA II and ORATORIO assessing Ocrevus in patients with RMS and PPMS earlier treated with IFN beta-1α or PBO respectively
  • Ocrevus resulted in suppression of relapse and MRI disease (16.1% vs 21.3% @5yrs.), suppression of T1-gadolinium enhancing (T1-Gd+) lesions (0.004 vs 0.49 @3yrs.) in RMS; In PPMS patients DP reduced to 96% and upper limb DP is 13.4% as measured by the nine-hole peg test (9-HPT) @24 wks.
  • Additionally, results from P-III CHORDS for RRMS showed no relapse, T1-Gd+ lesion MRI activity and N/E T2 lesion MRI activity with no 24-wks CDP @48wks. Ocrevus is approved in 68 countries including EU, Australia& Switzerland with awaited marketing approval in 20 countries

Click here to read full press release/article | Ref: Roche | Image: Roche Diagnostics

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post